newsfilter
← Latest News
ACCESS Newswire·

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic OptionsBy: Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / September 8, 2025 / Biodexa Pharmaceuticals PLC. , a late